================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                 AMENDMENT NO. 1
                                       TO
                                  FORM 10-KSB/A

                 [X] ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

                   For the fiscal year ended December 31, 2004

                        COMMISSION FILE NUMBER 001-14257


                                  XTRANA, INC.
             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

            DELAWARE                                             58-1729436
(State or Other Jurisdiction of                               (I.R.S. Employer
 Incorporation or Organization)                              Identification No.)

    P.O. BOX 668, SEDALIA, COLORADO                               80135
(Address of Principal Executive Offices)                        (Zip Code)

       Registrant's telephone number (including area code) (303) 466-4424

        Securities registered pursuant to section 12(b) of the Act: None

           Securities registered pursuant to section 12(g) of the Act:

                               TITLE OF EACH CLASS

                     Common Stock, par value $.01 per share

================================================================================
Check  whether the issuer (1) filed all reports  required to be filed by Section
13 or 15(d) of the  Exchange  Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports),  and (2) has been
subject to such filing requirements for the past 90 days. [X] Yes [_] No

Check if there is no disclosure of delinquent  filers in response to Item 405 of
Regulation  S-B is not  contained  in  this  form,  and no  disclosure  will  be
contained,  to the  best of  registrant's  knowledge,  in  definitive  proxy  or
information statements incorporated by reference in Part III of this Form 10-KSB
or any amendment to this Form 10-KSB. [X]

State Issuer's revenues for its most recent fiscal year: $102,000.

The aggregate market value of Xtrana, Inc. Common Stock, $.01 par value, held by
non-affiliates,  computed  by  reference  to the  average of the closing bid and
asked prices as reported by OTCBB on March 1, 2005, was $2,479,990.

Number of shares of Common  Stock of Xtrana,  Inc.,  $.01 par value,  issued and
outstanding as of March 31, 2005: 16,533,269.

Transitional Small Business Disclosure Format (Check one): Yes [_]; No [X]


<PAGE>


                                 AMENDMENT NO. 1
                  TO THE ANNUAL REPORT ON FORM 10-KSB FILED BY
                         XTRANA, INC. ON MARCH 31, 2005

         The  following  Items amend the Annual  Report on Form 10-KSB  filed by
Xtrana, Inc. (the "Company") on March 31, 2005 (the "Form 10-KSB"), as permitted
by the  rules  and  regulations  promulgated  by  the  Securities  and  Exchange
Commission. The Form 10-KSB is hereby amended to insert those Items as set forth
herein.  All  capitalized  terms  used  herein  but not  defined  shall have the
meanings ascribed to them in the Form 10-KSB.


                                    PART III

ITEM 9.  DIRECTORS AND EXECUTIVE OFFICERS;  COMPLIANCE WITH SECTION 16(A) OF THE
         EXCHANGE ACT

INFORMATION WITH RESPECT TO EACH DIRECTOR, NOMINEE AND CERTAIN OFFICERS.

         The following table sets forth certain information with respect to each
director, nominee and executive officer of the Company as of April 29, 2005.

                                                                     DIRECTOR/
                                                                     OFFICER
        NAME              AGE                POSITION                 SINCE
----------------------    ---    --------------------------------    --------

Michael D. Bick, Ph.D.    60     Chairman of the Board, Director      1991
James H. Chamberlain      57     Chief Executive Officer, Chief
                                   Financial Officer and Director     1998

Douglas L. Ayer           67     Director                             1993
John C. Gerdes, Ph.D.     56     Director                             2004
James B. Mahony           55     Director                             2002
N. Price Paschall         56     Director                             1997


         All officers are appointed by and serve at the  discretion of the Board
of  Directors.  There are no  family  relationships  between  any  directors  or
officers of the Company.

         MICHAEL D. BICK,  PH.D. was elected Chief  Executive  Officer in August
1991,  Chairman  of the  Board  in July  1993 and  President  in  January  1996.
Subsequent to the Company's  merger with Xtrana,  Inc. in August 2000,  Dr. Bick
retired as Chief Executive Officer and President.  In 1988, Dr. Bick founded the
Company's  former  subsidiary,  MeDiTech,  and was President and Chief Executive
Officer thereof until it was acquired by Biopool in January 1992.  Prior to that
date, he was  co-founder  and president of a privately  held medical device firm
for ten  years.  Dr.  Bick  received  a Ph.D.  in  molecular  biology  from  the
University of Southern  California in 1971 and was  affiliated  with the Harvard
Medical School and  Children's  Hospital  Medical Center in Boston  carrying out
research in human genetics from 1971 to 1974. Dr. Bick was a staff member of the
Roche  Institute of  Molecular  Biology  from 1974 to 1978.  Dr. Bick  currently
serves on the Board of  Counselors  of the  School of  Pharmacy,  University  of
Southern California.  Dr. Bick is also on the Board of Directors of Biotech.com,
a  privately   held   company   that   supplies   goods  and   services  to  the
biotech/biopharma industry.

         JAMES H. CHAMBERLAIN was appointed  interim Chief Executive Officer and
Chief  Financial  Officer of the Company in March 2004. Mr.  Chamberlain was the
founder of BioSource  International,  Inc., a California-based,  Nasdaq National
Market System company dedicated to the research, development, manufacturing, and
marketing of biomedical  products to the  diagnostic and research  markets.  Mr.
Chamberlain  founded  BioSource in 1989,  and retired as a director of BioSource
and as its Chairman, President, and Chief Executive


                                       2
<PAGE>


Officer in 2000. Prior to BioSource, Mr. Chamberlain was the Manager of Business
Development  for  Amgen,  Inc.  Mr.  Chamberlain  also  serves  on the  Board of
Directors of EcoSoil  Systems,  Inc., an  agricultural  biotechnology  firm. Mr.
Chamberlain  received a B.S.  degree in biology and chemistry from West Virginia
University  in  1969  and  completed  an MBA  Executive  Program  at  Pepperdine
University in 1981.

         DOUGLAS L. AYER has served as a member of the Board of Directors  since
1993.  Mr. Ayer is currently  President  and Managing  Partner of  International
Capital  Partners of Stamford,  CT. Mr. Ayer was  previously  Chairman and Chief
Executive  Officer of Cametrics,  a manufacturer of precision metal  components,
and has held  executive  positions at Paine Webber and McKinsey & Co.,  Inc. Mr.
Ayer also serves as a director of a number of private companies,  largely in the
information technology sector.

         JOHN C.  GERDES,  PH.D.  became a  director  and the  Chief  Scientific
Officer  concurrent  with the Company's  merger with Xtrana in 2000.  Dr. Gerdes
served as Chief  Scientific  Officer  until August  2004.  In 2003,  Dr.  Gerdes
resigned as a director of the Company  due, in part,  to his desire to submit an
offer for the purchase of the Company's  intellectual  property.  Dr. Gerdes was
reappointed  to the  Company's  Board of  Directors in March 2004.  In 1996,  he
conceived  of  a  unique  point  of  care  approach  for  DNA  diagnostics,  the
development of which resulted in the formation of Xtrana.  From 1988 to 1998, he
was the  Director of Paternity  Analysis  and Clinical  Director at IAD where he
supervised  clinical  testing and  introduced  PCR and other  nucleic acid based
clinical tests. He has twenty-one  publications  primarily  focused on molecular
methods of virus detection.  Dr. Gerdes received a B.S. in Microbiology from the
University  of Wyoming  in 1970,  and a Ph.D.  in  Microbial  Genetics  from the
University  of  California  at Los Angeles  (UCLA) in 1974.  After  completing a
four-year  post-doctoral  fellowship  in Virology,  again at UCLA, he spent four
years as an assistant  professor at the University of Colorado  Health  Sciences
Center in Denver  before  accepting a position at  Immunological  Associates  of
Denver (IAD), a specialty reference testing laboratory.

         JAMES B. MAHONY PH.D.  has served as a member of the Board of Directors
since  2002.  Dr.  Mahony  began his career  with the  University  of  Toronto's
Department of Microbiology  and  Parasitology,  and has held numerous  positions
with McMaster University,  including serving as the Director of the University's
Regional Virology and  Chlamydiology  Laboratory at St. Joseph's  Hospital.  Dr.
Mahony has authored 140  publications,  many of which deal with either chlamydia
or gonorrhea.  He has also  published 49 articles in books,  several  discussing
sexually transmitted diseases and chlamydia.  His laboratory frequently conducts
and  publishes  validation  studies of new  methods  for  detection  of sexually
transmitted  disease  infectious  agents. Dr. Mahony is currently a Professor in
the  Department of Pathology and  Molecular  Medicine at McMaster  University in
Hamilton, Ontario, Canada, and also serves as a member of the Professional Staff
of Hamilton Health Sciences Corporation,  Laboratory Medicine. In addition,  Dr.
Mahony is President Elect of the Pan American Society of Clinical Virology.

         N.  PRICE  PASCHALL  has  served as a member of the Board of  Directors
since 1997. Mr. Paschall is the founder and Managing  Partner of Context Capital
Group (formerly  HealthCare  Capital Advisors) since 1993. Context Capital Group
provides merger and acquisition  advice to middle market companies,  focusing on
the medical service industry. Prior to Context Capital Group, Mr. Paschall was a
Vice Chairman and founder of Shea, Paschall and Powell-Hambros Bank (SPP Hambros
& Co.), a firm  specializing in mergers and  acquisitions.  Mr. Paschall holds a
degree in business  administration  from  California  Polytechnic  University in
Pomona.  Since  1994,  Mr.  Paschall  has served on the Board of  Directors  and
provided certain  corporate  financial  services to Advanced  Materials Group, a
manufacturer   and   fabricator   of   specialty   foams,   foils,   films   and
pressure-sensitive adhesive components.

AUDIT COMMITTEE AND AUDIT COMMITTEE FINANCIAL EXPERT

         The  Audit   Committee  is  responsible   for  the  engagement  of  the
independent registered public accounting firm, reviews the scope of the audit to
be  conducted  by  the  independent   registered  public  accounting  firm,  and
periodically  meets with the independent  registered  public accounting firm and
the  Chief  Financial  Officer  to  review  matters  relating  to our  financial
statements,  our  accounting  principles  and our system of internal  accounting
controls,  and reports its  recommendations  as to the approval of the financial
statements to the Board of Directors.  The Audit Committee currently consists of
Messrs.  Bick,  Paschall and


                                       3
<PAGE>


Ayer.  Because our common stock is quoted on the OTC Bulletin  Board(R) (OTCBB),
we are not subject to the listing  requirements  of any  securities  exchange or
Nasdaq regarding the membership of our Audit Committee.  However, each member of
the Audit  Committee  is  independent  as  defined in Rule  4200(a)(15)  for the
listing standards of the Nasdaq Stock Market.  The Audit Committee does not have
a written charter.

         The  Board  of  Directors  has  determined  that  Mr.  Ayer is an audit
committee  financial expert, as defined in Item 401(e)(2) of Regulation S-B, and
is independent within the meaning of Item 401(e)(1)(ii) of Regulation S-B.

SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

         Section  16(a) of the  Securities  Exchange  Act of 1934,  requires our
executive  officers,  directors,  and persons who own more than ten percent of a
registered  class of our equity  securities  to file  reports of  ownership  and
changes in ownership  with the  Securities  and Exchange  Commission.  Executive
officers,  directors and  greater-than-ten  percent stockholders are required by
Securities  and Exchange  Commission  regulations to furnish us with all Section
16(a)  forms  they file.  Based  solely on our review of the copies of the forms
received by us and written  representations  from certain reporting persons that
they have  complied  with the relevant  filing  requirements,  we believe  that,
during the year ended December 31, 2004, all our executive  officers,  directors
and greater-than-ten percent stockholders complied with all Section 16(a) filing
requirements.

CODE OF ETHICS DISCLOSURE

         The Company has adopted a Code of Ethical  Conduct  which is applicable
to all  of its  officers,  directors  and  employees,  including  its  principal
executive officer, principal financial officer, principal accounting officer and
persons performing  similar functions.  A copy of the Code of Ethical Conduct is
filed as an exhibit to the Company's Annual Report on Form 10-KSB.

ITEM 10. EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION

         The following tables set forth certain  information as to the Company's
Chief Executive  Officer and Chief Financial Officer and former Chief Scientific
Officer (the "Named  Executive  Officers").  No other  executive  officer of the
Company had compensation in excess of $100,000 during the period:

<TABLE>
SUMMARY COMPENSATION TABLE

<CAPTION>
                                                   ANNUAL COMPENSATION           SECURITIES   OTHER
                                            ----------------------------------   UNDERLYING   COMPEN-
NAME AND PRINCIPAL POSITION       YEAR       SALARY       BONUS        OTHER(1)   OPTIONS     SATION
----------------------------      ----      --------    --------      --------    --------   --------
<S>                               <C>       <C>           <C>         <C>            <C>     <C>
James H. Chamberlain (2) ...      2004      $ 45,000        --        $ 31,300       --          --
   Chief Executive Officer &
   Chief Financial Officer

Timothy J. Dahltorp (3) ....      2004      $ 80,343        --            --         --      $200,000
   Chief Executive Officer        2003      $200,000        --            --         --          --
                                  2002      $200,000      20,000          --         --          --

John C. Gerdes, Ph.D. (4) ..      2004      $106,400        --        $  9,495       --      $ 36,400
   Chief Scientific Officer       2003      $145,600        --            --         --          --
                                  2002      $145,600        --            --         --          --
----------
<FN>
(1)      Consists of director fees and  reimbursement of expenses  incurred as a
         director.

(2)      Mr.  Chamberlain  was  appointed  CEO and CFO effective as of March 19,
         2004.


                                       4
<PAGE>


(3)      Mr. Dahltorp resigned from the Company, effective as of March 19, 2004.
         Other compensation in 2004 consists of severance payments.

(4)      Dr.  Gerdes  employment  with the Company  terminated  effective  as of
         August 15,  2004.  Other  compensation  in 2004  consists of  severance
         payments.
</FN>
</TABLE>


OPTION GRANTS IN LAST FISCAL YEAR

         No stock  options  grants  were  made to the Named  Executive  Officers
during the fiscal year ended December 31, 2004.

AGGREGATED  OPTION  EXERCISES  IN LAST  FISCAL YEAR AND FISCAL  YEAR-END  OPTION
VALUES

         The  following  table  sets  forth,  for  each of the  Named  Executive
Officers,  certain  information  regarding  the number of shares of common stock
underlying  stock options held at fiscal  year-end and the value of options held
at fiscal  year-end  based upon the last reported  sales price of the underlying
securities on the OTC Bulletin Board ($0.19 per share) on December 30, 2004, the
last trading day during 2004, as reported by the OTC Bulletin  Board. No options
were exercised by the Named Executive Officers during fiscal 2004.

<TABLE>
<CAPTION>
                                                                 VALUE OF UNEXERCISED
                              NUMBER OF UNEXERCISED OPTIONS          IN-THE-MONEY
                                      AT YEAR-END                OPTIONS AT YEAR-END(1)
                              -----------------------------   ---------------------------
NAME                           EXERCISABLE / UNEXERCISABLE    EXERCISABLE / UNEXERCISABLE
---------------------------   -----------------------------   ---------------------------
<S>                                    <C>                            <C>
James H. Chamberlain.......            170,000 / 0                    $ 0 / 0
Timothy J. Dahltorp (2)....               0 / 0                         --/--
John C. Gerdes, Ph.D.......               0 / 0                         --/--
----------
<FN>
(1)      Determined  as the  difference  between  the  closing  trade  price  on
         December 30, 2004  ($0.19/share) and the aggregate price of the options
         covering such shares.
(2)      Mr.  Dahltorp  resigned from the Company  effective March 19, 2004. All
         options held by Mr.  Dahltorp  terminated 90 days following the date of
         his resignation.
</FN>
</TABLE>

EMPLOYMENT AGREEMENTS WITH EXECUTIVE OFFICERS

         In March 2004,  we entered  into a consulting  agreement  with James H.
Chamberlain,  pursuant to which Mr.  Chamberlain  agreed to serve as our interim
Chief  Executive  Officer and interim  Chief  Financial  Officer.  The agreement
stipulates payments of $5,000 per month until a merger transaction is complete.

COMPENSATION OF DIRECTORS

         Non-employee  directors  receive $6,000 per calendar year,  plus $1,000
for  each in  person  Board  of  Directors  meeting  attended  and $250 for each
telephonic  Board  of  Directors   meeting   attended.   The  Company  pays  all
out-of-pocket fees of attendance.

EMPLOYEE BENEFIT PLANS

         The  Company  has  adopted  its 2000  Stock  Incentive  Plan (the "2000
Plan").  The  purpose of the 2000 Plan is to provide  incentives  and rewards to
selected eligible directors,  officers, employees and consultants of the Company
or its  subsidiaries  in order to assist the  Company  and its  subsidiaries  in
attracting,   retaining  and  motivating  those  persons  by  providing  for  or
increasing  the  proprietary  interests of those persons in the Company,  and by
associating  their  interests  in  the  Company  with  those  of  the  Company's
stockholders.


                                       5
<PAGE>


Currently,  the  maximum  number of shares  of common  stock  that may be issued
pursuant to awards granted under the 2000 Plan is 3,000,000,  subject to certain
adjustments to prevent  dilution.  The 2000 Plan authorizes its administrator to
enter into any type of  arrangement  with an eligible  participant  that, by its
terms,  involves  or might  involve the  issuance of options to purchase  common
stock,  common stock purchase  rights or any  combination of the foregoing.  Any
stock  option  granted may be an incentive  stock  option  within the meaning of
Section 422 of the Internal  Revenue Code of 1986,  as amended (the "Code") or a
nonqualified  stock  option.  The 2000 Plan  currently  is  administered  by the
Compensation  Committee  of our Board of  Directors.  As of December  31,  2004,
2,985,000  shares  of common  stock  remained  available  for grant of awards to
eligible participants under the 2000 Plan.

ITEM 11. SECURITY  OWNERSHIP OF CERTAIN  BENEFICIAL  OWNERS AND  MANAGEMENT  AND
         RELATED STOCKHOLDER MATTERS

BENEFICIAL OWNERSHIP OF COMMON STOCK

         The  following  table  sets  forth  as  of  April  29,  2005,   certain
information regarding the ownership of our common stock by (i) each person known
by us to be the beneficial  owner of more than 5% of the  outstanding  shares of
common stock, (ii) each of our directors,  (iii) each of our executive officers,
and  (iv)  all of our  executive  officers  and  directors  as a  group.  Unless
otherwise  indicated,  the address of each person shown is c/o Xtrana,  P.O. Box
668, Sedalia, Colorado 80135.

                                      NUMBER OF SHARES        PERCENT OF CLASS
                                     BENEFICIALLY OWNED      BENEFICIALLY OWNED
                                            (1)                     (2)
                                     ------------------      ------------------

DIRECTORS:
John C. Gerdes, Ph.D.............        1,430,068                 8.6%
Michael D. Bick, Ph.D............        1,092,950 (3)             6.7%
N. Price Paschall................          460,000 (4)             2.7%
Douglas Ayer.....................          332,884 (5)             2.0%
James H. Chamberlain.............          174,000 (6)             1.0%
James Mahony, Ph.D...............          110,000 (5)               *

5% HOLDERS:
Jack Wheeler.....................        1,143,544                 6.9%
Diane Kozwich....................        1,135,002                 6.9%

All directors and executive
   officers as a group
   (six persons).................        3,599,902 (7)            20.4%
----------
     *    Less than 1%.

     (1)  Under Rule  13d-3,  certain  shares  may be deemed to be  beneficially
          owned by more than one person  (if,  for  example,  persons  share the
          power to vote or the power to dispose  of the  shares).  In  addition,
          shares are deemed to be  beneficially  owned by a person if the person
          has the right to acquire the shares (for example,  upon exercise of an
          option)  within  60 days of the date as of which  the  information  is
          provided.  In computing the  percentage  ownership of any person,  the
          amount of shares outstanding is deemed to include the amount of shares
          beneficially  owned by such person (and only such person) by reason of
          these acquisition  rights. As a result,  the percentage of outstanding
          shares  of any  person  as shown in this  table  does not  necessarily
          reflect the person's actual  ownership or voting power with respect to
          the number of shares of common stock actually outstanding at April 29,
          2005.


                                       6
<PAGE>


     (2)  Percentage  ownership  is based on  16,533,269  shares of common stock
          outstanding  as of April 29, 2005.

     (3)  Consists of 70,000  shares of common stock subject to options that are
          currently  exercisable or that will become  exercisable within 60 days
          of April 29, 2005, and 1,022,950 shares held in the Bick Family Trust.

     (4)  Consists  of  275,000  shares of common  stock  subject  to  currently
          exercisable  warrants and 185,000  shares of common  stock  subject to
          options that are currently exercisable or that will become exercisable
          within 60 days of April 29, 2005.

     (5)  Consists  of  shares of  common  stock  subject  to  options  that are
          currently  exercisable or that will become  exercisable within 60 days
          of April 29, 2005.

     (6)  Includes  170,000  shares of common stock  subject to options that are
          currently  exercisable or that will become  exercisable within 60 days
          of April 29, 2005.

     (7)  Includes  867,884  shares of common stock  subject to options that are
          currently  exercisable or that will become  exercisable within 60 days
          of April 29,  2005,  and  275,000  shares of common  stock  subject to
          currently exercisable warrants.

         The information as to shares  beneficially  owned has been individually
furnished by the  respective  directors,  named  executive  officers,  and other
stockholders  of the company,  or taken from documents filed with the Securities
and Exchange Commission.

CHANGES OF CONTROL

         In December  2004,  we entered into a definitive  Agreement and Plan of
Merger with Alpha  Innotech  Corporation  pursuant to which Alpha Innotech would
merge with our wholly-owned subsidiary in a reverse merger transaction. Security
holders of Alpha  Innotech  would receive  shares of our common  stock,  and all
outstanding  Alpha  Innotech  stock options and warrants would be converted into
options and  warrants to purchase  our common  stock.  The closing of the merger
would result in a change of control in the Company.  Immediately  following  the
consummation of the transaction,  our stockholders  would own approximately 17%,
and the  shareholders  of Alpha  Innotech  would own  approximately  83%, of the
outstanding  shares of common stock of the combined company  (excluding  options
and  warrants).  Pursuant to the  definitive  agreement,  we also advanced Alpha
Innotech  Corporation  $500,000  pursuant  to a secured  promissory  note.  Upon
completion of the  transaction,  the Company is expected to change our corporate
name to Alpha Innotech Corp.  The closing of the merger  transaction  with Alpha
Innotech  Corporation  is subject to  approval  of the  stockholder  of both the
Company and Alpha Innotech Corporation.

SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS.

         The following table sets forth certain information regarding our equity
compensation plans as of December 31, 2004.

<TABLE>
<CAPTION>
                           NUMBER OF SECURITIES TO   WEIGHTED-AVERAGE EXERCISE       NUMBER OF SECURITIES
                           BE ISSUED UPON EXERCISE      PRICE OF OUTSTANDING        REMAINING AVAILABLE FOR
                           OF OUTSTANDING OPTIONS,     OPTIONS, WARRANTS AND     FUTURE ISSUANCE UNDER EQUITY
                             WARRANTS AND RIGHTS               RIGHTS                 COMPENSATION PLANS
-----------------------    -----------------------   -------------------------   ----------------------------
<S>                               <C>                          <C>                         <C>
Equity compensation
plans approved by
security holders.......           1,071,634                    $0.68                       2,985,000

Equity compensation
plans not approved by
security holders.......             674,755                    $0.90                          --
-----------------------    -----------------------   -------------------------   ----------------------------
Total..................           1,746,389                    $0.76                       2,985,000
</TABLE>

MATERIAL FEATURES OF EQUITY COMPENSATION PLANS NOT APPROVED BY STOCKHOLDERS:

         As of December 31, 2004,  the Company had 674,755  warrants to purchase
common stock outstanding and exercisable for prices ranging from $0.01 to $1.875
with a weighted  average  exercise  price of $0.9047  per  share.  The  weighted
average  remaining  contractual life of these warrants at December 31, 2004, was
2.9 years. These warrants have expiration dates ranging from 2005 to 2010.


                                       7
<PAGE>


ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

         Other than as described  below,  there are no proposed  transactions or
series of related  transactions,  nor were there any  transactions  or series of
related  transactions  during  fiscal 2003 and 2004,  to which the Company was a
party, in which the amount involved exceeded or will exceed $60,000 and in which
any director,  executive officer,  holder of more than 5% of our common stock or
any member of the immediate  family of any of the foregoing  persons had or will
have a direct or indirect material interest.

         In March 2004,  we entered into a consulting  agreement  with Mr. James
Chamberlain,  a member  of the  Board of  Directors,  pursuant  to which we have
engaged Mr.  Chamberlain as or interim Chief Executive Officer and interim Chief
Financial Officer. The agreement stipulates payments of $5,000 per month until a
merger transaction is complete.

ITEM 13. EXHIBITS

        EXHIBIT
          NO.                            DESCRIPTION
        ------    --------------------------------------------------------------
         2.1      Assignment  Agreement  dated  January  24,  2004  between  the
                  Company and Applera Corporation, though its Applied Biosystems
                  Group (7)

         2.1.1    First  Amendment to the Assignment  Agreement  dated March 31,
                  2004 between the Company and Applera Corporation,  through its
                  Applied Biosystems Group (9)

         2.2      Agreement and Plan of Merger dated as of December 14, 2004, by
                  and among the  Company,  AIC Merger Corp.  and Alpha  Innotech
                  Corporation (10)

         3.1      Certificate of Incorporation (1)

         3.2      By Laws (1)

         4.1      Shareholder Rights Plan (3)

         4.2      Second  Rights  Agreement  Amendment  between  the Company and
                  American Stock Transfer and Trust Company (11)

         10.1     1993 Stock Incentive Plan (2) *

         10.2     2000 Stock Incentive Plan (5) *

         10.4     Lease Agreement - Broomfield, Colorado (6)

         10.4.1   Lease  Addendum  Two  for   Modification  of  Rent  and  Early
                  Termination  of Lease  dated  November  11,  2003  between the
                  Company  and James M.  Roswell  d/b/a  Burbank  East  Business
                  Par.(7)

         10.4.2   Lease  Addendum  Three  for  Modification  of Rent  and  Early
                  Termination  of Lease  dated  February  12,  2004  between the
                  Company and James M. Roswell  d/b/a Burbank East Business Park
                  (7)

         10.5     Secured  Promissory Note Dated December 16, 2004 made by Alpha
                  Innotech Corporation in favor of the Company (Previously filed
                  on Form 10-KSB)

         10.6     Pledge and General Security  Agreement dated December 16, 2004
                  between Alpha Innotech Corporation and the Company (Previously
                  filed on Form 10-KSB)

         14.1     Code of Ethical Conduct (8)

         23.1     Consent  of  Independent  Auditors  (Previously  filed on Form
                  10-KSB)

         24.1     Power of Attorney (Previously filed on Form 10-KSB)

         31.1     Certificate of our Chief Executive Officer and Chief Financial
                  Officer pursuant to Rule 13a-14(a).

         32.1     Certificate of our Chief Executive Officer and Chief Financial
                  Officer pursuant to Rule 13a-14(b).  (Previously filed on Form
                  10-KSB)
         ----------
         *        Indicates a management contract or compensatory plan.
         (1)      Incorporated  by  reference to the  Registrant's  Registration
                  Statement on Form S-1 (File No. 33-20584).
         (2)      Incorporated by reference to the Registrant's Annual Report on
                  Form 10-KSB for the fiscal year ended December 31, 1994.
         (3)      Incorporated by reference to Registrant's  Form 8-A filed June
                  26, 1998.
         (4)      Incorporated by reference to the Registrant's Annual Report on
                  Form 10-KSB for the fiscal year ended December 31, 1999.


                                       8
<PAGE>


         (5)      Incorporated  by reference to  Registrant's  Definitive  Proxy
                  Statement filed on June 23, 2000.
         (6)      Incorporated  by  reference  to  Registrant's  Form 8-K  filed
                  January 25, 2001.
         (7)      Incorporated by reference to Registrant's Form 10-KSB filed on
                  March 19, 2004.
         (8)      Incorporated  by reference to the  Registrant's  Form 10-KSB/A
                  filed on April 28, 2004.
         (9)      Incorporated by reference to the  Registrant's  Form 8-K filed
                  on May 24, 2004.
         (10)     Incorporated by reference to the  Registrant's  Form 8-K filed
                  on December 17, 2004.
         (11)     Incorporated by reference to the  Registrant's  Form 8-K filed
                  January 5, 2005.

ITEM 14. PRINCIPAL ACCOUNTANT AND FEES

SERVICES PROVIDED BY THE INDEPENDENT AUDITORS

         The audit  committee of our Board of Directors is  responsible  for the
appointment,   compensation,   retention  and  oversight  of  the  work  of  the
independent  auditors.  Accordingly,  the audit  committee has appointed  Hein &
Associates  LLP to perform  audit and other  services  for the  Company  and its
subsidiaries.

         AUDIT FEES.  The  aggregate  fees billed by Hein &  Associates  LLP for
professional  services rendered for the audit of our annual financial statements
and review of  financial  statements  included in our Form  10-QBS's or services
that are normally  provided in connection with statutory and regulatory  filings
were $25,562 for fiscal year 2003 and $39,170 for fiscal year 2004.

         AUDIT-RELATED  FEES.  Hein & Associates LLP did not bill us for any for
professional  services  rendered for assurance and related  services  reasonably
related to the  performance  of the audit or review of our financial  statements
(other than those reported above) for fiscal years 2003 and 2004.

         TAX  FEES.  The  aggregate  fees  billed by Hein &  Associates  LLP for
professional  services rendered for tax compliance,  tax advice and tax planning
were $5,150 for fiscal year 2003 and $8,140 for fiscal year 2004.

         ALL OTHER FEES.  In fiscal years 2003 and 2004,  Hein & Associates  LLP
did not bill us for any other services performed for us during the periods.

         The audit committee  approved all of the foregoing services provided by
BDO Seidman LLP.

POLICY REGARDING PRE-APPROVAL OF SERVICES PROVIDED BY THE INDEPENDENT AUDITORS

         The  audit  committee  has  established  a  general,   informal  policy
requiring  it's  pre-approval  of all audit services and  permissible  non-audit
services  provided by the independent  auditors,  along with the associated fees
for  those  services.  For  both  types of  pre-approval,  the  audit  committee
considers  whether the provision of a non-audit  service is consistent  with the
SEC's rules on auditor independence,  including whether provision of the service
(i) would  create a mutual  or  conflicting  interest  between  the  independent
auditors  and the  Company,  (ii) would  place the  independent  auditors in the
position  of  auditing  its own work,  (iii)  would  result  in the  independent
auditors  acting in the role of management or as an employee of the Company,  or
(iv) would place the independent auditors in a position of acting as an advocate
for the  Company.  Additionally,  the  audit  committee  considers  whether  the
independent  auditors  are best  positioned  and  qualified  to provide the most
effective  and  efficient  service,  based on  factors  such as the  independent
auditors' familiarity with our business,  personnel, systems or risk profile and
whether  provision of the service by the independent  auditors would enhance our
ability to manage or control risk or improve audit quality or would otherwise be
beneficial to us.


                                       9
<PAGE>


                                   SIGNATURES


         In  accordance  with  Section  13 or 15(d)  of the  Exchange  Act,  the
registrant  caused  this  report to be signed on its behalf by the  undersigned,
thereunto duly authorized.

                                   Xtrana, Inc.


Date:    May 2, 2005               BY:  /S/ JAMES H. CHAMBERLAIN
                                        ---------------------------------------
                                   James H. Chamberlain
                                   Chief Executive Officer and Chief Financial
                                   Officer

         In accordance with Section 13 or 15(d) of the Exchange Act, this report
has been signed below by the following  persons on behalf of the  registrant and
in the capacities and on the dates indicated.


/S/ MICHAEL D. BICK          Chairman of the Board of Directors      May 2, 2005
-------------------------
Michael D. Bick, Ph.D.


/S/ JAMES H. CHAMBERLAIN     Chief Executive Officer, Chief          May 2, 2005
-------------------------    Financial Officer and Director
James H. Chamberlain


         *                   Director                                May 2, 2005
-------------------------
Douglas L. Ayer


         *                   Director                                May 2, 2005
-------------------------
N. Price Paschall


         *                   Director                                May 2, 2005
-------------------------
John C. Gerdes, Ph.D.


         *                   Director                                May 2, 2005
-------------------------
James Mahony, Ph.D.


         * By:   /S/ JAMES H. CHAMBERLAIN
                 --------------------------
                  James H. Chamberlain
                  As Attorney-In-Fact


                                       10